

PRIOR AUTHORIZATION CRITERIA

BRAND Name
(generic)

(acamprosate calcium)

Status: CVS Caremark Criteria
Type: Initial Prior Authorization

POLICY

FDA-APPROVED INDICATIONS

Acamprosate calcium is indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence that are abstinent at treatment initiation. Treatment with acamprosate calcium should be part of a comprehensive management program that includes psychosocial support.

The efficacy of acamprosate calcium in promoting abstinence has not been demonstrated in subjects who have not undergone detoxification and not achieved alcohol abstinence prior to beginning acamprosate calcium treatment. The efficacy of acamprosate calcium in promoting abstinence from alcohol in polysubstance abusers has not been adequately assessed.

COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- Patient has a diagnosis of alcohol dependence AND the requested drug will be prescribed as part of a comprehensive psychosocial treatment program

AND

- The patient is, or the patient will be, abstinent from alcohol at treatment initiation

AND

- The patient has experienced an inadequate treatment response, intolerance, or contraindication to naltrexone

REFERENCES

1. Acamprosate calcium [package insert]. Pennington, NJ: Zydus Pharmaceuticals USA Inc.; May 2017.
2. AHFS DI (Adult and Pediatric) [database online]. Hudson, OH: Lexi-Comp, Inc.; http://online.lexi.com/lco/action/index/dataset/complete_ashp [available with subscription]. Accessed October 2017.
3. Micromedex Solutions [database online]. Greenwood Village, CO: Truven Health Analytics Inc. Updated periodically. www.micromedexsolutions.com [available with subscription]. Accessed October 2017.
4. Prescribing Medications for Alcohol Dependence Excerpt from Helping Patients Who Drink Too Much: A Clinician's Guide. U.S. Department of Health and Human Services, National Institutes of Health National Institute on Alcohol Abuse and Alcoholism. NIH Publication 07–3769. www.niaaa.nih.gov/guide. October 2008 Update. Accessed October 2017.
5. Naltrexone [package insert]. Durham, NC: Accord Healthcare, Inc.; February 2014.
6. Pharmacotherapy for Adults with Alcohol-Use Disorders in Outpatient Settings - Research Protocol. AHRQ Effective Health Care Program. <http://www.effectivehealthcare.ahrq.gov/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productid=1483>. April, 26, 2013. Accessed October 2017.
7. Jonas DE, Amick HR, Feltner C, et al. Pharmacotherapy for Adults With Alcohol Use Disorders in Outpatient Settings A Systematic Review and Meta-analysis. *JAMA*. 2014;311(18):1889–1900.
8. Donoghue K, Elzerbi C, Saunders R, et al. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis. *Addiction*. 2015;110: 920-930.
9. Salisbury-Afshar E. Implementing AHRQ Effective Health Care Reviews: Pharmacotherapy for Adults with Alcohol Use Disorder. *American Family Physician*. 2016;94(2): 155-157.